Smith+Nephew to showcase JOURNEY™ II Unicompartmental Knee System at ESSKA Congress 2022
Designed using cutting edge computer simulation to maintain normal motion and function, JOURNEY II
"The ground-breaking introduction of a lateral-specific baseplate design in conjunction with a ten size range for femoral and tibial components makes JOURNEY II
Paired with proprietary OXINIUM™ Technology, JOURNEY II
"Smith+Nephew has a successful legacy in the development of unicompartmental knee solutions and our JOURNEY II
Invitation to Smith+Nephew ESSKA Lunch Symposium on 29 April
- Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR). Hip, Knee & Shoulder Arthroplasty: 2021 Annual Report.
Adelaide: AOA, 2021.
- National Joint Registry for
England, Wales, Northern Irelandand the Isle of Man. 18th Annual Report. 2021. Hertfordshire, UK.
- Capra R,
Bini SA, Bowden DE, et al. Implementing a perioperative efficiency initiative for orthopedic surgery instrumentation at an academic center: A comparative before-and-after study. Medicine ( Baltimore). 2019;98(7):e14338.
- Smith+Nephew 2019. Instrument Tray Design Verification. Internal Report. TR1496.
- Smith+Nephew 2019. Optimus Tray Design Description. Internal Report. DD0066.
- Nherera L, Verma S,
Trueman P. Cost-effectiveness of robotic-assisted unicompartmental knee arthroplasty (r-UKA) using NAVIOTM compared to traditional unicompartmental knee arthroplasty (t-UKA) for patients with unicompartmental osteoarthritis. Poster presented at: ISPOR 18-22 May, 2019; New Orleans, Los Angeles, USA.
* We thank the patients and staff of all the hospitals in
Based on a Markov model of 100 patients, revision rates based on: a retrospective, multi-center study, n=128 for NAVIO™ Surgical System;
Note: Evidence referenced in this release used ZUK data and is not specific to JOURNEY II
Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people's bodies and their self-belief by using technology to take the limits off living. We call this purpose 'Life Unlimited'. Our 18,000 employees deliver this mission every day, making a difference to patients' lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global franchises of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: risks related to the impact of COVID-19, such as the depth and longevity of its impact, government actions and other restrictive measures taken in response, material delays and cancellations of elective procedures, reduced procedure capacity at medical facilities, restricted access for sales representatives to medical facilities, or our ability to execute business continuity plans as a result of COVID-19; economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers (including, without limitation, as a result of COVID-19); price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers (including, without limitation, as a result of COVID-19); competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the
Trademark of Smith+Nephew. Certain marks registered